Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
AssigneeBristol-Myers Squibb Company
InventorMaria Jure-Kunkel
Life of this patent
Estimating the term…
Abstract
Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
Claims8
A method for diminishing the incidence or severity of immunotherapy-dependent colitis associated with anti-CTLA4 therapy comprising administering to a mammal in need thereof a combination comprising the sequential administration of a therapeutically effective amount of an agonistic CD137 antibody, followed by the administration of a therapeutically effective amount of an antagonistic CTLA-4 antibody, wherein the incidence or severity of immunotherapy-dependent colitis associated with anti-CTLA4 therapy is diminished.
Dependencies are inferred from the claim text.